Multiomic Analysis of Methylation and Transcriptome Reveals a Novel Signature in Esophageal Cancer

Yi-qi Jin and Dong-liu Miao

Abstract

Background: Epigenetic alterations have been shown to lead to human carcinogenesis. The aim of this study was to perform an integrative analysis to develop an epigenetic signature to predict overall survival (OS) of esophageal cancer.

Methods: DNA methylation and messenger RNA expression data of esophageal cancer samples were downloaded from The Cancer Genome Atlas database and were incorporated and analyzed using an R package MethylMix. Functional enrichment analysis of the methylation-related differentially expressed genes (DEGs) was performed. Epigenetic signature and nomogram associated with the OS of esophageal cancer were established by the multivariate Cox model.

Results: A total of 71 methylation-related DEGs were identified. Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that these genes were involved in the biological process related to the initiation and progression of esophageal cancer. Two-gene (FAM24B and FAM200A) risk signature for OS was developed by multivariate Cox analysis, of which had high accuracy. The signature is independent of clinicopathological variables and indicated better predictive power than other clinicopathological variables. Moreover, we developed a novel prognostic nomogram based on risk score and 3 clinicopathological factors.

Conclusions: Our study indicated possible methylation-related DEGs and established an epigenetic signature, which may provide novel insights for understanding the pathogenesis of esophageal cancer.

Keywords

epigenetics, DNA methylation, differentially expressed genes, esophageal cancer, risk score system, prognosis

Background

As one of the deadly diseases, esophageal cancer (EC), characterized by highly lethal, is the eighth most common cancer worldwide.1 Esophageal squamous cell carcinoma and adenocarcinoma are 2 major histological types of EC. The World Health Organization reported the estimated about 17 290 new cases and 15 850 EC deaths in 2018 from global cancer statistics.2 Despite significant advances in treatment methods, the prognosis of patients with EC remains unfavorable, even after tumor resection.3 Therefore, a deeper understanding of initiation and progression, as well as the discovery of new molecular markers associated with EC, could lead to the identification of new therapeutic strategies to regulate this deadly disease.

Alterations in epigenetic modifications are closely related to tumor development.3 Aberrant DNA methylation is the most widely studied epigenetic mechanism. Unlike genetic mutations, the process of DNA methylation is reversible and is therefore considered a promising research tool for cancer research.6 Transcriptional silencing caused by abnormal hypermethylation of the tumor suppressor gene promoter region is considered to be an important mechanism of tumorigenesis.7 Generally, abnormal DNA methylation in cancer can be divided into 2 categories: focal areas of hypermethylation and widespread areas of hypomethylation. These epigenomic aberrations contribute to the pathogenesis of EC through different mechanisms.3,8 Focal areas of hypermethylation occurs preferentially at promoter cytosine-
phosphate-guanine (CpG) islands and leads to gene inactivation in the absence of changes to genetic sequence. Compared to focal hypermethylation, much less is known about global hypomethylation. This is because most methylation studies are performed using candidate gene methods. Nowadays, due to the regulatory relationships between the DNA methylation and gene expression, several methylation-regulated differentially expressed genes (DEGs) have been identified in EC. However, there are still no quantitative signatures for prognosis of EC. The aim of this study was to perform an integrative analysis to identify epigenetic changes that may play key role in the initiation and progression of EC using DNA methylation and messenger RNA (mRNA) expression profiles and to develop an epigenetic signature to predict overall survival (OS) of EC.

### Materials and Methods

#### Data Source

The DNA methylation, RNA-seq data, and clinicopathological data of EC from the The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). DNA methylation data generated with the Illumina Infinium HumanMethylation450 platform and mRNA expression was evaluated based on the level 3 RNA-seq data. A total of 198 samples (183 tumor samples and 15 normal samples) of DNA methylation, 169 samples (159 tumor samples and 10 normal samples) of mRNA expression, and clinicopathological data of 183 patients were obtained. Patients with uncertain tumor location (n = 1), tumor stage (n = 22), and tumor grade (n = 34) were excluded. After matching the clinical data with methylation and mRNA expression data, data from 126 patients with EC were finally reserved for further study. The clinicopathologic characteristics of the study cohort are shown in Table 1. The flowchart of the overall research strategy is shown in Figure 1.

### Table 1. Clinicopathologic Characteristics of Patients With Esophageal Cancer.

| Variables                        | Case, n (%)          |
|----------------------------------|----------------------|
| Total                            | 126                  |
| Age (M ± SD, years)              | 60.456 ± 10.96       |
| Gender                           |                      |
| Female                           | 18 (14.3)            |
| Male                             | 108 (85.7)           |
| History of Barrett esophagus     |                      |
| No                               | 74 (58.7)            |
| Yes                              | 19 (15.1)            |
| Unknown                          | 33 (26.2)            |
| History of reflux disease        |                      |
| No                               | 74 (58.7)            |
| Yes                              | 23 (18.3)            |
| Unknown                          | 29 (23.0)            |
| Histological type                |                      |
| Esophagus adenocarcinoma         | 43 (34.1)            |
| Esophagus squamous cell carcinoma| 83 (65.9)            |
| Esophageal tumor central location|                      |
| Proximal                         | 6 (4.8)              |
| Mid                              | 42 (33.3)            |
| Distal                           | 78 (61.9)            |
| Tumor status                     |                      |
| Tumor free                       | 82 (65.1)            |
| With tumor                       | 44 (34.9)            |
| Grade                            |                      |
| I                                | 17 (13.5)            |
| II                               | 70 (55.5)            |
| III                              | 39 (31.0)            |
| Stage                            |                      |
| I                                | 9 (7.1)              |
| II                               | 67 (53.2)            |
| III                              | 44 (34.9)            |
| IV                               | 6 (4.8)              |

**Differential Expression Analysis and Correlation Analysis**

The “limma” package in R software was used to identify DEGs and aberrant methylated genes (differently methylated genes [DMG]) based on the thresholds of fold change (FC) > 1.5 and adjusted P value < .05 and FC > 1 and adjusted P value < .05, respectively. MethylMix is a program designed to identify methylation events related to gene expression. We explored the association between DNA methylation and gene expression. Pearson coefficient between methylation level (β value) and gene expression level was calculated to find significantly negatively related genes using the MethylMix package in R. Pearson coefficient < −0.3 with P < .05 was set as the criterion for methylation-related DEGs identification.
Gene Ontology and Pathway Analysis

To better understand the function of methylation-related DEGs, we performed the Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis using “clusterProfiler” package in R. A P value of <.05 was considered significant.

Development of Risk Assessment Signature Based on Gene Methylation Levels

Univariate and multivariate Cox regression analyses were performed to identify a prognostic model based on their methylation β value. Mathematical models were established based on the Akaike Information Criterion using the “Survival” R package. A P value of <.05 was considered significant.

Development of Risk Assessment Signature Based on Gene Methylation Levels

Univariate and multivariate Cox regression analyses were performed to identify a prognostic model based on their methylation β value. Mathematical models were established based on the Akaike Information Criterion using the “Survival” R package. We calculated the prognostic risk score as follows: Risk score = ∑(β value (Genei) × Coefficient (Genei)). Based on the median risk score value, all patients were classified into high-risk score group and low-risk score group. Overall survival curves of the 2 groups were generated using Kaplan-Meier analysis. The predictive value of the prognostic model was evaluated by time-dependent receiver operating characteristic (ROC) curve analysis using the “survival ROC” R package.

Construction of Prognostic Nomogram

To provide clinicians with a quantitative method to predict a patient’s prognosis, we established a genomic-clinical nomogram to predict the OS of each patient with EC individually. The distinguishing ability of the nomograms was evaluated by the area under the curve (AUC) of ROC curve. The calibration curves were plotted to compare the nomogram-predicted survival with the actual survival.

Results

Identification of Methylation-Related EDGs

According to the criteria (FC > 1.5 and adjusted P value < .05), a total of 6261 DEGs (5119 upregulated genes and
1142 downregulated genes) were identified between EC and normal samples. We explored the association between the DNA methylation and gene expression to identify methylation-related DEGs (Pearson coefficient $< -0.3$ and $P < .05$). Pearson coefficient between methylation level ($\beta$ value) and gene expression for each of the 6261 DEGs was calculated. Finally, 71 methylation-related DEGs were obtained (Figure 2). The distribution map of the top differential methylation is demonstrated in Figure 3, and the association between gene expression and DNA methylation of the top methylation-related DEGs is shown in Figure 4.

**Functional Enrichment Analysis**

A total of 71 methylation-related DEGs in patients with EC were annotated according to the GO database. The result demonstrated that these genes were enriched in 260 GO terms ($P < .05$). The top 10 enriched terms were shown in Figure 5A. According to the KEGG pathway analysis, 7 pathways were associated with these genes (Figure 5B, $P < .05$). These enriched pathways were pathways in carbon metabolism, Janus kinase–signal transducer and activator of transcription (JAK-STAT) signaling pathway, herpes simplex virus 1 infection, PPAR signaling pathway, proteoglycans in cancer, and peroxisome.

**Construction of Epigenetic Signature Based on Gene Methylation Levels**

In order to contrive multigenes-based signature for predicting OS in EC, univariate and multivariate COX analyses were performed with the 71 genes. The result showed that 2 genes were significant prognostic factors for EC. An epigenetic signature was established based on the methylation $\beta$ values of the 2 genes as follows: risk score $= (-3.281 \times$ methylation $\beta$ value of FAM24B) $+ (2.207 \times$ methylation $\beta$ value of FAM200A). All the patients were assigned to low-risk group and high-risk group based on median risk scores. The risk score distribution, survival status, and expression profile of the 2 prognostic genes are shown in Figure 6A. The Kaplan-Meier curves illustrated that there were significant differences in OS in the training cohort (Figure 6B). The AUC value of the signature was 0.738 which showed the predictive ability of the signature in predicting survival risk of patients with EC (Figure 6C).

**Construction of Prognostic Nomogram**

Univariate Cox analysis showed that the tumor status, tumor stage, and risk score were significantly correlated with OS ($P < .05$). According to the results based on the multivariate analysis, 4 variables (histological type, tumor status, tumor stage, and risk score) were confirmed as independent predictors for OS (Table 2). These significant variables were used to create the nomogram for 3- and 5-year OS (Figure 7). By
adding up the scores related to each variable and projecting total scores to the bottom scales, it is easy to calculate the estimated 3- and 5-year OS probabilities. Time-dependent ROC at 3- and 5-years was conducted to confirm that the nomogram had higher sensitivity and specificity in predicting the prognosis of OS than AJCC staging system. The 3- and 5-year AUC values of the nomogram for OS were 0.835 and 0.878, compared with 0.755 and 0.705, for that of AJCC stage (Figure 8A). The calibration curves for the probability of OS of 3 years or 5 years show no obvious deviations from the reference line, which illustrated optimal agreement between model prediction and actual observations (Figure 8B).

**Discussion**

In this study, we performed a comprehensive analysis to develop an epigenetic signature for stratifying the risk of recurrence of EC. First, we identified DMGs and DEGs between EC samples and normal samples. By integrating DNA methylation and mRNA expression data, we identified 71 methylation-
related DEGs. Functional enrichment analysis showed that these genes were involved in the biological process related to initiation and progression of EC. After univariate and multivariate Cox proportional hazards analyses, 2 of these genes with independent prognostic value were selected to construct an epigenetic signature. Furthermore, the proposed risk score is independent of clinicopathological variables and showed a favorable prognostic ability. Then, the nomogram based on the risk score and 3 clinicopathological factors as a method to predict prognosis provides a useful method for predicting OS in patients with EC. These results indicate that the signature may serve as an independent prognostic factor.

Many oncogenes and cancer suppressor genes show irregular expression due to abnormal CpG island methylation in the regulatory region of DNA rather than sequence changes. Due to the stable nature of DNA and its amplification, DNA methylation can be easily converted from laboratory settings to routine hospital operations. Furthermore, the methylation profile of gene promoters is different for each type of cancer, suggesting that detection of abnormal gene promoter methylation can be used as a potential molecular biomarker for cancers. In addition, epigenetic changes expected to be therapeutic targets as epigenetic changes are reversible. Therefore, detecting DNA methylation can provide new insights for further assessing cancer risk and treatment. Accumulating evidence suggests that DNA methylation is involved in the initiation and progression of EC and is associated with clinical outcomes. Promoter hypermethylation silences tumor suppressor genes, including coding genes (PTPN6, RHCG, and ZNF471) and noncoding genes (lncRNA ZNF667-AS1 and ZNF667, microRNA-128, and microRNA-10b-3p). Liu et al indicated that PTPN6 expression was significantly downregulated in EC cell lines and tissues. The expression of PTPN6 in EC cells treated with DNA methyltransferase inhibitor was significantly upregulated, and frequent methylation of CpG sites in the P2 promoter was detected in esophageal squamous-cell carcinoma (ESCC) tissues and cell lines. The aberrant methylation of P2 showed significant tumor specificity and was associated with the expression level of PTPN6. The hypermethylation status and low expression of PTPN6 are related to advanced clinicopathological features and poor prognosis in patients with ESCC. Liu et al found methylation frequencies of CpG sites within proximal promoter of lncRNA ZNF667-AS1 and ZNF667 were significantly higher in ESCC tissues. The methylation status was linked to tumor stage, tumor grade, and prognosis. Multivariate Cox analysis revealed that hypermethylation was an independent indicator for poor prognosis. They further confirmed that promoter hypermethylation inhibited the expression of ZNF667-AS1 and ZNF667. The expression of ZNF667-AS1 and ZNF667 was significantly downregulated in ESCC tissue. Silence of ZNF667-AS1 and ZNF667 promoted the viability, migration, and invasion of EC cells in vitro. Taken together, ZNF667-AS1 and ZNF667 may act as tumor suppressors in ESCC. CDKN2B and TFF1 are hypermethylated during early stages of EC and might therefore serve as biomarkers for early diagnosis of EC. Plasma samples of patients suspected of having ESCC might be collected and analyzed for these hypermethylation events. Dong et al revealed that the hypermethylation within the proximal promoter of ZNF667-AS1 or ZNF667 influenced the binding ability of transcription factor E2F1 binding and the following transcriptional activation and expression of them. Compared with single DNA

Figure 5. Enrichment of top GO terms (A) and KEGG pathways (B) of methylation-regulated genes. GO indicates Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
methyltransferase inhibitor treatment or E2F1 overexpression, DNA methyltransferase inhibitor combined with E2F1 overexpression significantly upregulated the expression levels of ZNF667-AS1 and ZNF667.

In this study, we identified a total of 71 methylation-regulated DEGs. Kyoto Encyclopedia of Genes and Genomes pathways suggested these genes were mainly enriched in JAK-STAT signaling pathway, carbon metabolism, herpes simplex virus 1 infection, PPAR signaling pathway, proteoglycans in cancer, and peroxisome. The JAK/STAT signaling pathway is a central signaling hub that can be activated by a plethora of cytokines, growth factors, and hormones and is associated with cell proliferation, differentiation, and apoptosis. It consists of 7 mammalian STAT family members that act as transcription factors and are activated by 4 different JAKs. The dysregulation of the JAK/STAT signaling pathway has been

**Figure 6.** Construction of the epigenetic signature in esophageal cancer. A, Risk score distribution, survival status of each patient, and expression heat map of the 2 genes. B, Kaplan-Meier estimates of the overall survival. C, Time-dependent ROC curve of the prognostic signature. ROC indicates receiver operating characteristic.

**Table 2.** Univariate and Multivariate Survival Analyses for Screening Independent Prognostic Factors.

| Variable                                      | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | HR (95% CI)         | P         | HR (95% CI)         | P         |
| Age (M ± SD, years)                           | 1.008 (0.983-1.034) | .517     | 1.026 (0.993-1.060) | .120     |
| History of Barrett’s esophagus (no/yes/unknown) | 1.085 (0.704-1.673) | .712     | 1.291 (0.802-2.078) | .293     |
| History of reflux disease (no/yes/unknown)    | 1.006 (0.675-1.499) | .979     | 0.817 (0.529-1.262) | .363     |
| Histological type (EA/ESCC)                   | 1.031 (0.540-1.969) | .927     | 5.231 (1.648-16.714) | .005     |
| Tumor location (proximal/mid/distal)          | 1.242 (0.622-2.477) | .539     | 2.073 (0.794-5.401) | .136     |
| Tumor status (tumor free/with tumor)          | 2.341 (1.414-3.876) | .001     | 2.917 (1.370-6.214) | .006     |
| Grade (I/II/III/IV)                           | 1.276 (0.781-2.084) | .330     | 1.324 (0.701-2.501) | .387     |
| Stage (I/II/III/IV)                           | 2.398 (1.553-3.703) | <.001    | 2.000 (1.150-3.479) | .014     |
| Risk score (high/low)                         | 2.102 (1.313-3.366) | .002     | 3.102 (1.704-5.645) | <.001     |

Abbreviations: EA, esophagus adenocarcinoma; ESCC, esophageal squamous-cell carcinoma; HR, hazard ratio; SD, standard deviation.
Figure 7. Nomogram for predicting 3- and 5-year overall survival in esophageal cancer.

Figure 8. A. Area under the curve values of ROC predicted 3-year and 5-year overall survival rates of nomogram and AJCC stage. B. Calibration curves for the probability of overall survival of 3 and 5 years. ROC indicates receiver operating characteristic.
implicated in the initiation and progression of various cancers, including EC.33-35 Yu et al found that the JAK-STAT pathway was significantly reduced by unbiased RNA sequencing in RNF168-depleted EC cell. Silence of RNF168 reduces JAK-STAT target genes, such as IRF1, IRF9, and IFITM1. Immunoprecipitation showed that RNF168 associates with STAT1 in the nucleus, stabilizing the STAT1 protein and inhibiting its ubiquitination and degradation. Liu et al revealed that nimesulide inhibited the growth of EC cells by inactivating the JAK2/STAT3 pathway. FAM24B and FAM200A in our signature have not been reported in previous studies to relate to EC biology, thus the functions and mechanisms of the 2 genes in EC need to be further investigated.

Several limitations of this study need to be pointed out. First, the prognostic signature or nomogram was established based on data from TCGA database. However, due to the limited number of patients in this study, a large sample validation cohort is needed to further validate the predictive accuracy of our model. Second, although the signature of the 2 genes showed favorable predictive ability in EC, the mechanism behind it was not yet clear and further researches are needed. Further functional experiments in vivo and vitro are needed to investigate the elusive mechanisms of aberrant methylated pathways caused by the 2 genes.

Conclusions
The present study develops a novel genetic signature via the analysis integrating multiomic data including DNA methylation, transcriptome, and clinical outcome of patients with EC from TCGA database. Moreover, a nomogram combining the epigenetic signature and clinicopathological factors was constructed to visually predict the survival of patients with EC.

Authors’ Note
Y.Q.J. and D.L.M. designed the manuscript, performed experiments, analyzed, and interpreted data, and wrote the manuscript. The final manuscript was read and approved by all authors. The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Approval by Ethics Committee would not be necessary because all data were downloaded from public data in the TCGA databases.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Suzhou team introduction project (No. SZYJTD201712).

ORCID iD
Dong-liu Miao https://orcid.org/0000-0002-8564-1012

References
1. Abbas G, Krasna M. Overview of esophageal cancer. Ann Cardiotorac Surg. 2017;6(2):131-36.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
3. Thallinger CMR, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011;29(35):4709-4714.
4. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062-5067.
5. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-692.
6. Ning B, Li W, Zhao W, Wang R. Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin. 2016;48(1):97-109.
7. Pan Y, Liu G, Zhou F, Su B, Li Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 2018;18(1):1-14.
8. Lin DC, Wang MR, Koeffler HP. Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients. Gastroenterology. 2018;154(2):374-389.
9. Dong Z, Liang X, Wu X, et al. Promoter hypermethylation-mediated downregulation of tumor suppressor gene SEMA3B and IncRNA SEMA3B-AS1 correlates with progression and prognosis of esophageal squamous cell carcinoma. Clin Exp Metastasis. 2019;36(3):225-241.
10. Gonzaga IM, Soares Lima SC, Nicolau MC, et al. Hypermethylation and decreased expression in esophageal squamous cell carcinoma and histologically normal tumor surrounding esophageal cells. Clin Epigenetics. 2017;9:130.
11. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98(4):288-295.
12. Pan Y, Song Y, Cheng L, Xu H, Liu J. Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma. J Cell Biochem. 2019;120(12):19482-19495.
13. Yu G, Wang LG, Han Y, He QY. Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284-287.
14. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. J Biometrics. 2000;56(2):337-344.
15. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009;20(4):555-561.
16. Hervouet E, Peixoto P, Delage-Mouroux R, Boyer-Guitaut M, Carton PF. Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clin Epigenetics. 2018;10:17.
17. Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer. 2011;11(10):726-734.
18. Liu L, Zhang S, Liu X, Liu J. Aberrant promoter 2 methylation-mediated downregulation of protein tyrosine phosphatase,
non-receptor type 6, is associated with progression of esophageal squamous cell carcinoma. Mol Med Rep. 2019;19(4):3273-3282.

19. Ming XY, Zhang X, Cao TT, et al. RHCG Suppresses tumorigenicity and metastasis in esophageal squamous cell carcinoma via inhibiting NF-κB signaling and MMP1 expression. Theranostics. 2018;8(1):185-198.

20. Sun R, Xiang T, Tang J, et al. 19q13 KRAB zinc-finger protein ZNF471 activates MAPK10/JNK3 signaling but is frequently silenced by promoter CpG methylation in esophageal cancer. Theranostics. 2020;10(5):2243-2259.

21. Dong Z, Li S, Wu X, et al. Aberrant hypermethylation-mediated downregulation of antisense lncRNA ZNF667-AS1 and its sense gene ZNF667 correlate with progression and prognosis of esophageal squamous cell carcinoma. Cell Death Dis. 2019;10(12):930.

22. Jin J, Guo T, Guo Y, Liu J, Qu F, He Y. Methylation-associated silencing of miR-128 promotes the development of esophageal cancer by targeting COX-2 in areas with a high incidence of esophageal cancer. Int J Oncol. 2019;54(2):644-654.

23. Lu YF, Yu JR, Yang Z, et al. Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC). J Exp Clin Cancer Res. 2018;37(1):301.

24. Tokugawa T, Sugihara H, Tani T, Hattori T. Modes of silencing of p16 in development of esophageal squamous cell carcinoma. Cancer Res. 2002;62(17):4938-4944.

25. Lima SCS, Hernández-Vargas H, Simão T, et al. Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. Epigenetics. 2011;6(10):1217-1227.

26. Li B, Wang B, Niu LJ, Jiang L, Qiu CC. Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics. 2011;6(3):307-316.

27. Li D, Zhang L, Liu Y, et al. Specific DNA methylation markers in the diagnosis and prognosis of esophageal cancer. Aging. 2019;11(23):11640-11658.

28. Blattler A, Farnham PJ. Cross-talk between site-specific transcription factors and DNA methylation states. J Biol Chem. 2013;288(48):34287-34294.

29. Domcke S, Bardet AF, Adrian Ginno P, Hartl D, Burger L, Schübeler D. Competition between DNA methylation and transcription factors determines binding of NRF1. Nature. 2015;528(7583):575-579.

30. Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374-384.

31. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1-2):1-24.

32. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328.

33. Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers. 2019;11(12):2002.

34. Jiang L, Zhao XH, MaoYL, Wang JF, Zheng HJ, You QS. Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6. J Exp Clin Cancer Res. 2019;38(1):465.

35. Yu N, Xue M, Wang W, et al. RNF168 facilitates proliferation and invasion of esophageal carcinoma, possibly via stabilizing STAT1. J Cell Mol Med. 2019;23(2):1553-1561.